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Abstract
Background: Hypertension control through pharmacological treatment has led to substantial benefits in the
prevention of morbidity and mortality from cardiovascular diseases. However, evidence from a number of studies
suggests that as many as 50 to 80 % of patients treated for hypertension have low adherence to their treatment
regimen. The objective of this systematic review is to evaluate the effectiveness of medication adherence interventions
for hypertension. In addition, we aim to explore what barriers and facilitators in the interventions may have been
targeted and how these might be related to the effect size on blood pressure (BP).
Methods: This review is a hypertension-specific update to the previous Cochrane Review by Nieuwlaat et al. (2014)
on interventions to enhance medication adherence. A systematic literature search will be carried out, and two authors
will independently screen titles and abstracts for their eligibility for inclusion and independently extract data from
the selected studies and assess the methodological quality using the Cochrane Collaboration Risk of Bias Tool. A
meta-analysis will be conducted, and additionally, theoretical factors in interventions will be identified using the
Theoretical Domains Framework.
Discussion: This review will generate new information by quantitatively evaluating the effectiveness of adherence
interventions for hypertension and potentially identify which theoretical domains are associated with more effective
interventions and which domains have not been the subject of intervention development.
Systematic review registration: PROSPERO CRD42016033358
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Background
Rationale
Description of the condition
Hypertension, also known as high or raised blood pressure
(BP), is a condition in which the blood vessels have persist-
ently raised pressure. Epidemiologic studies demonstrate
that cardiovascular disease events (e.g. stroke, heart failure
and coronary heart disease) are associated with hyperten-
sion [1, 2]. A systematic review by Kearney et al. [3] found
it to be an important risk factor for more serious conditions
that carry greater risk of disability and death (primarily
cardiovascular and cerebrovascular events) and the single
most important modifiable risk factor for stroke and myo-
cardial infarction in both developed and developing coun-
tries. It is estimated that hypertension affects one billion
people worldwide [4].
Hypertension control through pharmacological treat-
ment has led to substantial benefits in the prevention of
morbidity and mortality from cardiovascular disease [5]. A
Cochrane review conducted by Musini et al. [6] was an
assessment of all the trials of blood pressure lowering
therapy in people with hypertension aged 60 years and over
and found that these treatments reduced death, strokes and
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heart attack. However, despite the efficacy of antihyperten-
sive agents, there is a significant problem of non-adherence
to these medications in those diagnosed with hypertension;
therefore, the effectiveness of current treatment is limited.
The World Health Organization (WHO) defines adher-
ence to long-term therapy as ‘the extent to which a per-
sons behaviour – taking medication, following a diet and/
or executing lifestyle changes – corresponds with agreed
recommendations from a health care provider’ [7]. High
adherence (defined as medication possession ratio of 80 to
100 %) to hypertensive medications is associated with
higher odds of blood pressure control compared with
those with medium or low levels of adherence [8]. Evi-
dence from a number of studies suggests that as many as
50 to 80 % of patients prescribed pharmacological antihy-
pertensive therapy have low adherence to their treatment
regimen [9]. Vrijens et al. [10] used medication event
monitor system (MEMS) data to measure adherence to
antihypertensive medications and found that about half of
all patients prescribed the medications stopped taking
them within one year of the initial prescription. They also
found that on any one day, 10 % of patients omitted
their scheduled dose of medication. According to the
WHO, this lack of adherence to antihypertensive medi-
cation is the most important cause of failure to achieve
BP control [7].
Description of the interventions
Interventions for enhancing medication adherence in
hypertension can have multiple components, such as edu-
cation around the condition and the importance of adher-
ence, skills development, combination pills, provision of
practical support and self-monitoring of blood pressure.
These interventions have had mixed results (e.g. [11, 12]).
Conn et al. [13] conducted a meta-analysis combining
randomised and non-randomised studies that targeted
anti-HT medication adherence improvement and found
that 112 intervention vs control group comparisons had a
standardised mean difference effect size of 0.3 (SD 0.079)
on adherence. However, there was significant heterogen-
eity across studies (I2 = 87 %), which can be explained by
heterogeneity in samples, designs and measures used to
assess adherence.
How the intervention might work
Because interventions for adherence in hypertension can
have very varied and often multiple components, it can be
difficult to ascertain which factors are causing the interven-
tion to work or are masking effective components. Behav-
ioural theory can be used to gain an understanding of the
effects of the behaviour change intervention. However,
papers rarely report the explicit use of theory despite inter-
ventions almost certainly involving at least an implicit idea
of what factors to address to instigate change [14]. This
means that even if an intervention is successful, it is diffi-
cult to understand the behaviour change processes respon-
sible and therefore to inform future intervention design,
refinement and application. Consequently, it may be of
benefit to retrospectively identify which barriers and facili-
tators adherence interventions report targeting and the
extent to which such factors map onto pre-existing theor-
etical factors. In order to capture the potential range of
possible targeted factors, a sufficiently broad framework of
theoretical factors is required. The Theoretical Domains
Framework (TDF) is an integrative framework which was
developed and validated to summarise the range of psy-
chological theory underpinning behaviour change into
distinct factors [15, 16]. By applying the TDF to adherence
interventions, it may be possible to explore which theoret-
ical domains modify effect size (e.g. [14, 17]).
Why it is important to do this review
There are two reasons why it is important to do this review.
Firstly, it is a hypertension-specific update to the previous
Cochrane review by Nieuwlaat et al. [18] on interventions
to enhance medication adherence. This was an extremely
large review, encompassing all medical conditions. Due to
the heterogeneity of outcomes across conditions, it was not
feasible to conduct a meta-analysis as part of the research.
As this study is focusing specifically on hypertension, it is
anticipated that most of the included interventions will
have a common outcome of change in blood pressure in
addition to the outcome of medication adherence. This will
allow quantitative synthesis and additional analysis that was
not possible in the previous review. Secondly, to the best of
our knowledge, identifying whether the targeting of particu-
lar theoretical domains in the interventions is associated
with greater effect sizes in adherence interventions in
hypertension has not been done previously. Recent studies
have attempted to synthesise existing evidence using a simi-
lar general approach (e.g. Little et al. [14] used the TDF
within a systematic review of interventions to improve
quality of care in post-fracture investigation.) This will be a
valuable addition to the literature as it may inform future
intervention design.
Objectives
The objective of this review is to evaluate the effectiveness
of adherence interventions for hypertension and explore
which specific barriers and facilitators the interventions
may have been targeting and how this tailored approach
might be related to the effect size on blood pressure (pri-
mary outcome) and medication adherence.
Methods
Eligibility criteria
This protocol has been developed in line with the Preferred
Reporting Items for Systematic Review and Meta-Analysis
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Protocols (PRISMA-P) statement [19] (see Additional file 1).
The systematic review and meta-analysis will be conducted
and reported in accordance with the PRISMA statement
[20] and is registered with the PROSPERO (International
Prospective Register of Systematic Reviews) database (regis-
tration number CRD42016033358).
Types of studies
The systematic review is a condition-specific update to the
large review by [18] on interventions to enhance medica-
tion adherence which searched for studies until January
2013. This review will include randomised controlled trials
(RCTs) that provide unconfounded tests of interventions
expected to enhance adherence. Studies will be included
regardless of treatment intensity or duration, mode of treat-
ment delivery or medium of treatment.
Types of participants
The participants will be patients who were prescribed medi-
cation for hypertension.
Types of interventions
Interventions of any sort intended to affect adherence with
prescribed, self-administered medication for the treatment
of hypertension.
Types of outcome measures
The primary outcome will be the change in blood pressure
(SBP, DBP, or both) at 6 months compared with baseline
readings taken prior to the intervention. The change in BP
may be reported as a dichotomous (% with positive/nega-
tive BP change) or continuous variable (mean change in BP
values). The primary outcome will be compared between
treatment groups, i.e. the difference between groups regard-
ing the change in BP.
The secondary outcome will be medication adherence
measured by at least one of the following: self-report, pill
count, pharmacy refill records and electronic medication
monitors (MEMS).
Interventions will have to include both outcomes to be
included.
Follow-up completion
Regarding follow-up completion, studies will need to have
at least 80 % follow-up during at least 6 months. The 80 %
data completion is required for both blood pressure and
adherence outcomes.
Information sources
Search methods for identification of studies
We will search The Cochrane Library including CENTRAL,
MEDLINE, EMBASE, PsycINFO, CINAHL and Sociological
Abstracts. This database search will be a hypertension-
specific update on previous searches that were undertaken
on 1 September 1993, 12 December 1993, 1 June 1994, 30
June 1995, 31 July 1998, 15 August 2001, 30 September
2004, 1 February 2007 and 11 January 2013. We will search
new publications since 11 December 2012, that is, having a
1-month overlap with the previous search. All databases
were originally searched from their start date. Ongoing trials
will be identified by checking trials and protocols published
in relevant databases of current ongoing clinical research
studies, specifically World Health Organization International
Clinical Trials Registry Platform and ClinicalTrials.gov.
Search strategy
The search filters for each database can be seen in Appendix
1. We will check articles cited in reviews and original studies
of patient adherence in hypertension. We will contact au-
thors of included RCTs to identify additional studies.
Study records
Data management
We will use a web-based data management system, devel-
oped by the Health Information Research Unit at McMaster
University to facilitate screening, data extraction, adjudica-
tion of disagreements, author review and confirmation of
data, production of data tables and production of data files
for future research use. This system has been successfully
used in conducting and completing several large, complex
systematic reviews.
Selection process
We will re-assess all RCTs on hypertension included in
the 2014 update for eligibility to carry over into the
current update. Retrieved citations from the updated
search will enter a first screening stage. Based on the title
and abstract, studies will move to the second screening
stage if they meet all five eligibility criteria or if there is
uncertainty about their eligibility. In the second screening
stage, assessment of the full text will determine if studies
will be included on the review. At both screening stages,
two independent review authors (EM and HD) will assess
eligibility and an adjudicator (TN) will resolve disagree-
ments. We will record reasons for excluding citations in
the second screening stage and report these in a PRISMA
flow chart.
Data collection and analysis
Data collection process
We will import data from the 2014 review into the update
database and check the data for accuracy. Extracted data
includes items as provided in the tables from the previous
review [18]: the ‘characteristics of included studies’ table
(i.e. methods, participants, interventions, outcome, add-
itional notes pertaining to any one of the aforementioned
items, detailed assessment of risk of bias), the ‘adherence
and outcome’ table (i.e. intervention, control, effect on
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adherence outcome, effect on clinical outcome) and risk
of bias summary. We will extract the same items for the
new included studies. Two review authors (EM and HD)
will independently extract all new data and an adjudicator
(TN) will resolve disagreements. We will contact primary
or corresponding authors of all included RCTs to confirm
extracted data and provide missing data.
The TDF domains that appeared to be targeted by the
interventions and within the control groups will be identi-
fied and coded independently by two reviewers (EM and
GM), using a data extraction form designed for the pur-
pose. This will be based on similar work by Little et al. [14].
We will use domains as well as constructs within domains
to inform coding decisions within domains, using construct
definitions as described by Cane et al. [16]. The data extrac-
tion form will be tested on one included study. The coding
of each domain will be supported by evidence from the
text. Inter-rater reliability will be calculated prior to resolv-
ing discrepancies. Discrepancies will be discussed until
100 % agreement is achieved.
Assessment of risk of bias in included studies
Two authors (EM and HD) will independently use the
Cochrane ‘Risk of bias’ tool described in The Cochrane
Handbook for Systematic Reviews of Interventions [21] to
assess randomisation procedures, bias, allocation, outcome
assessors, reporting of findings and losses to follow-up.
Measures of treatment effect
For the primary outcome of BP, we will report mean differ-
ences between groups and the 95 % confidence intervals
(95 % CI).
For the secondary outcome of medication adherence,
it is likely that different measurement tools will have
been used and so we will calculate the standardised
mean difference and the 95 % CI for continuous data.
Where no standard deviations are reported, we will calcu-
late the standard deviations using the methods described in
The Cochrane Handbook for Systematic Reviews of Interven-
tions [21].
Unit of analysis issues
In studies where more than one intervention group is con-
tained in one comparator arm, we will include both inter-
ventions (providing they are relevant to the review) and will
split the number of participants between the two groups
accordingly. Where cluster RCTs are included for analysis
we will use appropriate statistical analysis methods to ac-
count for the cluster effect as described in The Cochrane
Handbook for Systematic Reviews of Interventions [21].
Assessment of heterogeneity
We will use the I2 statistic and the Chi2 test to assess
heterogeneity as described in The Cochrane Handbook for
Systematic Reviews of Interventions [21]. We will initially
carry out a qualitative analysis of the heterogeneity of the
study groups by study design e.g. number of randomised
groups and data collection methodology e.g. measurement
strategy to assess adherence. We will quantitatively analyse
suitable data subsequently using regression analysis.
Assessment of reporting bias
We will assess reporting bias initially by a visual inspec-
tion of funnel plots and use of appropriate statistical tests
as described in The Cochrane Handbook for Systematic
Reviews of Interventions [21]. Some studies may not report
absolute blood pressure changes, but rather proportional
changes from the baseline measurement or another par-
ameter. In these cases, we will also consider reporting bias.
Data synthesis
Data will be pooled and analysed where appropriate and
feasible. We will analyse each outcome measure separ-
ately, calculate intervention effects and express them as
relative risks with 95 % confidence intervals for dichotom-
ous data and as mean differences and standardised mean
differences (if required) with 95 % confidence intervals for
continuous data. We will give consideration to the use of
random-effects models that can be incorporated into the
statistical analysis if substantive statistical heterogeneity is
identified. In addition, we will use subgroup analyses to
assess heterogeneity (see below).
The relationship between the number of different do-
mains coded and the effect size of the intervention will be
explored using Pearson correlations (two-tailed). This ana-
lysis will be based on similar work by Little et al. [14]. The
maximum possible number of different domains coded will
be 14 (the number of TDF domains). The number of
different domains coded in the control group will be sub-
tracted from the number of different domains coded in the
intervention group. A sensitivity analysis will be performed
in which the subtraction of control groups was not done,
to examine the effect of the subtraction on the result. The
analysis will also explore the potential for weighting do-
mains according to the frequency of which the domain was
targeted. If no significant difference emerges, the primary
approach to data synthesis will be descriptive e.g. identify-
ing the proportion of studies that target specific domains.
Subgroup analysis
We anticipate that different categories of interventions
will be used by the included studies, including context of
the intervention delivery, technological interventions,
combination pill and service provision interventions. If
appropriate, we will use subgroup analysis to categorise
these interventions and to explore heterogeneity. Simi-
larly, some studies may only target low adherers while
others target all hypertension patients. If numbers allow,
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subgroup analysis will also be conducted here. If feasible,
similar patient sub-group analysis will also be conducted
on age and gender.
Discussion
This proposed review will add to the literature in several
ways. Due to population growth, ageing and behavioural
risk factors, such as unhealthy diet, harmful use of alcohol,
lack of physical activity, excess weight and exposure to per-
sistent stress, there has been a significant growth in the in-
cidence of hypertension; the number of people with
hypertension rose from 600 million in 1980 to 1 billion in
2008 [22]. Issues around the control and management of
hypertension are becoming increasingly pertinent, in high-
income countries and even more so in low- and middle-
income countries.
As previously discussed, interventions for medication ad-
herence in hypertension tend to be multi-factorial and there
is no ‘one’ recommended strategy for enhancing adherence
[18]. It is possible that by mapping intervention components
to the TDF we may be able to determine which theoretical
factors are associated with larger effect sizes. A systematic
review, also using the TDF, by Khatibet al. [23] examined
patient and healthcare provider barriers to hypertension
awareness, treatment and follow-up. While this analysis of
quantitative and qualitative studies provides valuable infor-
mation, it is possible that self-reported barriers are not
always the critical determinants of non-adherence, and
therefore, interventions targeting these factors may not be
effective. This current review will be an important follow-up
on to this, as we will be able to see if the barriers and facili-
tators reported by the patients and providers are the same
barriers and facilitators that have been targeted in interven-
tion RCTs and which intervention targets are associated
with larger effect sizes. This will have a stronger potential to
inform future intervention development and clinical practice
in the area.
There are limitations to retrospectively coding interven-
tions. It is likely that some of the interventions will not
employ or fail to report explicit use of theory, as seen in a
similar systematic review on adherence by Holmeset al.
[24]. This means that coding will have to be based on
inference from the text. This may also be challenging as
preliminary review of some of the relevant interventions
show that some of them are lacking comprehensive
descriptions of the intervention content. However, all au-
thors will be contacted and asked to provide more infor-
mation and intervention manuals where possible. Also,
coding will be carried out by two reviewers to allow for
better sensitivity and enhanced reliability of the theoretical
content. Another limitation of this review is that it only
includes RCTs. This is the highest quality evidence, but
large population and policy interventions are typically not
tested in RCTs and thus not captured. As organizational/
policy interventions are part of a wider approach to behav-
iour change intervention, our focus on RCTs where individ-
uals or clusters are randomised to treatments is appropriate.
Using a more heterogenous set of study designs and inter-
vention approaches would lead to a less coherent and de-
fensible synthesis of study findings. This review will provide
the highest quality evidence for specific intervention tech-
niques that should be part of larger programmes of policies,
if proven effective. A final limitation is the observational
nature of this work, any association found between domains
and effect size will be correlational and as such, causation
cannot be inferred.
This review will be of interest to researchers, health pro-
fessionals, healthcare commissioners and patient groups. It
will generate new information by quantitatively evaluating
the effectiveness of adherence interventions for hyper-
tension and potentially identify which theoretical do-
mains are associated with more effective interventions
and which domains have not been the subject of inter-
vention development.
Appendix 1
MEDLINE search filters used in this update using the Ovid
interface:
1. ((exp patient compliance/ OR (patient adj compliance)
.tw. OR (patient adj adherence).tw. OR (medication
adj compliance).tw. OR (medication adj adherence)
.tw.) AND ((clinical trial OR random:).mp. OR tu.xs.))
NOT ((qualitative OR retrospective OR mice OR rat
OR rats).tw. OR editorial.pt. OR letter.pt. OR com
ment.pt.) NOT (animals NOT humans).sh. (Note: clini
cal trial.mp. picks up clinical trial.pt.)
2. ((random: OR control:).mp. AND (exp patient
compliance/ OR patient dropouts/ OR psychotherapy/
OR treatment refusal/ OR patient education/ OR regi
men:.tw.) AND (intervention: OR outcome:).tw. AND
(medicat:.tw. OR drug therapy/)) NOT ((qualitative
OR retrospective OR mice OR rat OR rats).tw. OR
editorial.pt. OR letter.pt. OR comment.pt.) NOT (ani
mals NOT humans).sh.
3. ((exp hypertension/ OR (blood adj pressure).ti. OR
hypertens$.ti OR/1-3))
CINAHL search filters used in this update using the
EBSCO interface:
1. MH patient compliance +OR TI ‘patient compliance’
OR AB ‘patient compliance’ OR TI ‘patient adherence’
OR AB ‘patient adherence’ OR TI ‘medication com
pliance’ OR AB ‘medication compliance’ OR TI ‘medi
cation adherence’ OR AB ‘medication adherence’ NOT
PT editorial or PT letter or TI qualitative or AB
qualitative or TI retrospective or AB retrospective or
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TI mice or AB mice or TI rat or AB rat or TI rats or
AB rats (limited by Clinical Queries therapy sensitive
search filter and date—2007 to 2012 )
2. MH patient compliance OR MH medication
compliance OR MH patient dropouts OR MH
treatment refusal OR MH patient education OR TI
psychotherapy OR AB psychotherapy AND TX (
(random* OR control*) ) AND TX ( (medicat* OR
drug therapy) ) NOT PT editorial or PT letter or TI
qualitative or AB qualitative or TI retrospective or
AB retrospective or TI mice or AB mice or TI rat
or AB rat or TI rats or AB rats
3. MH hypertension OR TI hypertension OR AB
hypertension OR MH ‘blood pressure’ OR TI ‘blood
pressure’ OR AB ‘blood pressure’ NOT PT editorial
or PT letter or TI qualitative or AB qualitative or
TI retrospective or AB retrospective or TI mice or
AB mice or TI rat or AB rat or TI rats or AB rats
EMBASE search filter used in this update using the
Ovid interface: (random: or control:).mp. AND (patient
compliance or patient dropouts or illness behavior or
psychotherapy or treatment refusal or patient education
or regimen:).mp. AND(intervention: or outcome: or treat-
ment outcome).mp. AND(medicat: or drug therapy).mp.
AND (clinical trial or controlled study or randomised con-
trolled trial).mp. AND (hypertension or hypertens$ or
blood pressure).mp.
PsycINFO search filter used in this update using the
Ovid interface: (((control: or random:).tw. or exp treat-
ment/) and (adherence or compliance or noncompli-
ance or dropouts or patient education).mp. and (drug
therapy or drug or medicat: or treatment or regimen).mp.
and (intervention or outcomes or treatment outcomes)
.mp.) not (qualitative or retrospective or mice or rat or
rats).tw. AND (hypertension or hypertens$ or blood pres
sure).mp.
The Cochrane Library search filter used in this update
(http://onlinelibrary.wiley.com/cochranelibrary/search/):
((random*) AND (complian* or adheren* or pharmaco-
therapy or regimen* or educat*) AND (medicat*) AND
(hypertension or hypertens$ or blood pressure) (Note:
Searched using all text tag; Search by product: Cochrane
Database of Systematic Reviews, DARE (Other Reviews),
Central; Search by record: all)
Sociological Abstracts search filter used in this update
using the ProQuest interface (http://search.proquest.-
com/socabs/advanced): ((patient or treatment or drop-
outs) AND (clinical trials or control) AND (drugs or
medicine or medication) AND (hypertension or hyper-
tens$ or blood pressure) (Searched using all fields;
all(medication) retrieves su(medication adherence)
ClinicalTrials.gov search filter used in this update (http://
clinicaltrials.gov/ct2/search/advanced):
‘patient compliance’ OR ‘patient adherence’ OR ‘medi-
cation compliance’ OR ‘medication adherence’ AND
‘hypertension’ OR ‘blood pressure’ | Closed Studies |
Studies With Results |
International Clinical Trials Registry Platform search
filter used in this update (http://apps.who.int/trialsearch/
AdvSearch.aspx): patient compliance or patient adher-
ence or medication compliance or medication adherence
and hypertension or blood pressure (Note: recruitment
status all used)
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